Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1707 • ACR Convergence 2024
TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease
Stephanie Glavaris, Alexander Pearlman, Jin Liu, Jiaxin Ge, Yuanxuan Xia, Kyle J. Kaeo, Tolulope Awosika, Colin Gliech, Tushar Nichakawade, Nikita Marcou, Chetan Bettegowda, Drew Pardoll, Kenneth W. Kinzler, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Therapies that indiscriminately deplete all T cells carry a high risk of opportunistic infection, precluding their widespread use in T cell-mediated autoimmune diseases. Targeting…
Abstract Number: 2311 • ACR Convergence 2024
Higher Rates of Psoriatic Arthritis in Patients with Calcium Pyrophosphate Deposition Disease Than Controls: A Retrospective Cohort Study in US Veterans
Natalie Anumolu¹, Ann Rosenthal¹, Katherine Sherman² and Shikha Singla¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²Research Division, Zablocki Veterans Affairs, Milwaukee
Background/Purpose: CPPD has been shown to complicate other types of inflammatory arthritis such as rheumatoid arthritis. However, only a few studies have investigated the correlation…
Abstract Number: 2328 • ACR Convergence 2024
Do Patients That Develop PsA Before Psoriasis Have Different Disease Outcomes?
Fadi Kharouf¹, Virginia Carrizo Abarza², Shangyi Gao³, Daniel Pereira⁴, Richard Cook⁵, Vinod Chandran⁶ and Dafna Gladman⁷, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Waterloo, Waterloo, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Most patients with Psoriatic Arthritis (PsA) experience psoriasis (Ps) before the onset of arthritis. However, in about 15% of the cases, the skin and…
Abstract Number: 2345 • ACR Convergence 2024
Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis
Andre Lucas Ribeiro¹, Virginia Carrizo Abarza², Dafna Gladman³, Vinod Chandran⁴ and Lihi Eder⁵, ¹Women's College Hospital & University of Toronto, Porto Alegre, Rio Grande do Sul, Brazil, ²Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a complex inflammatory disease where achieving remission remains challenging despite multiple approved biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs).…
Abstract Number: 2581 • ACR Convergence 2024
Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study
Hejian Zou¹, Weiguo Wan², Yu Xue¹, Lingyun Sun³, Ning Zhang⁴, Haiying Chen⁵, Xiaofei Shi⁶, Shengyun Liu⁷, Lin Chen⁸, Xinmei Ma⁹, Hua Wei¹⁰, Zhenyu Jiang¹¹, Xiaomei Li¹², Hongtao Fan¹³, Hongbin Li¹⁴, Jingyang Li¹⁵, Rui Wu¹⁶, Guixiu Shi¹⁷, Jing Zhu¹⁸, Xiaodan Kong¹⁹, Yuewu Lu²⁰, Xiaojing Cui²¹, Qianning Zheng²¹, Xiaoyan Bai²² and Guangchao Dong²¹, ¹Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China (People's Republic), ²Huashan Hospital, Fudan University, Shanghai, China (People's Republic), ³Dept of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing Univ Medical School, Nanjing, CN, Nanjing, China (People's Republic), ⁴Shengjing Hospital Affiliated to China Medical University, Shenyang, China (People's Republic), ⁵The Third Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic), ⁶The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China (People's Republic), ⁷The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic), ⁸Jilin Province People's Hospital, Changchun, China (People's Republic), ⁹Zaozhuang Municipal Hospital, Zaozhuang, China (People's Republic), ¹⁰Subei People's Hospital of Jiangsu Province, Yangzhou, China (People's Republic), ¹¹The First Hospital of Jilin University, Changchun, China (People's Republic), ¹²The First Affiliated Hospital of the University of Science and Technology of China, Hefei, China (People's Republic), ¹³The First People's Hospital of Yunnan Province, Kunming, China (People's Republic), ¹⁴Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ¹⁵Zhuzhou Central Hospital, Zhuzhou, China (People's Republic), ¹⁶The Tirst Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China (People's Republic), ¹⁷The First Affilated Hospital of Xiamen University, Xiamen, China (People's Republic), ¹⁸Sichuan Provincial People's Hospital, Chengdu, China (People's Republic), ¹⁹The Second Affiliated Hospital of Dalian Medical University, Dalian, China (People's Republic), ²⁰BeiJing Chao-Yang Hospital, Capital Medical University, Beijing, China, ²¹Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China (People's Republic), ²²Jiangsu Hengrui Pharmaceuticals Co., Ltd., Beijing, China
Background/Purpose: Patients with psoriasis often develop psoriatic arthritis (PsA), a chronic systemic inflammatory disease with a severe clinical burden that impairs quality of life. In…
Abstract Number: 0221 • ACR Convergence 2024
The Significance of Tenderness with or Without Swelling of Finger Joints in Relation to Magnetic-resonance-imaging, Ultrasound and X-ray in Psoriatic Arthritis
Victoria Furer¹, iris Eshed², Moshe iluz¹, Ori Elkayam³ and Ari Polachek⁴, ¹Tel-Aviv Medical Center, Tel-Aviv, Israel, ²Sheba Medical Center, Tel Hashomer affiliated with School of medicine, Tel Aviv University, Department of Diagnostic Imaging, Tel Aviv, Israel, ³Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁴Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel
Background/Purpose: The musculoskeletal involvement in psoriatic arthritis (PsA) can involve both articular and extra articular structures manifested by inflammatory and structural lesions. The relationship between…
Abstract Number: 0584 • ACR Convergence 2024
Effectiveness of Tofacitinib Monotherapy versus Combination Therapy in Patients with Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondylarthritis Registry
Alexis Ogdie¹, Nicole Middaugh², Taylor Blachley², Tran Bourgeois³, You-Li Ling⁴, Rajiv Mundayat⁴, Lara Fallon⁵, Karim Masri⁶ and Philip Mease⁷, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Real-world (RW) data on the effectiveness of tofacitinib in patients (pts) with PsA are limited. This study summarized disease activity and pt‑reported outcome measures…
Abstract Number: 0606 • ACR Convergence 2024
Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis Not Associated with Risk of Major Adverse Cardiac Events
Bonit Gill¹, Jack Geiger¹, Jean Liew², Michael Putman³ and Shikha Singla¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²Boston University, Boston, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Individuals with psoriasis or psoriatic arthritis (PsO/PsA) have an elevated risk ofmajor adverse cardiac events (MACE), which include congestive heart failure (CHF), myocardialinfarction (MI),…
Abstract Number: 1232 • ACR Convergence 2024
Patient Reported Impact of Psoriatic Arthritis and Desired Treatment Outcomes
Elizabeth Luce¹, Beth schneider² and Dianna cronin², ¹MyHealthTeam, San Francisco, CA, ²MyHealthTeams, San Francisco, CA
Background/Purpose: People living with psoriatic arthritis often struggle with the physical and mental health toll. Understanding the holistic impact of psoriatic arthritis is crucial to…
Abstract Number: 1463 • ACR Convergence 2024
Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies
A. Francesca Setiadi¹, Maggie Burhans², Xuguang Hu², Stephen Colgan³, Kim Notari², Marcia C. Teixeira dos Santos², Apostolos Kontzias², Sue Cheng² and Nehal Mehta⁴, ¹Amgen Inc., South San Francisco, CA, ²Amgen Inc., Thousand Oaks, CA, ³Amgen, Halton Hills, ON, Canada, ⁴The George Washington University School of Medicine, Washington, DC
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with higher rates of obesity and cardiometabolic complications. Apremilast (APR) is an inhibitor of phosphodiesterase 4,…
Abstract Number: 1709 • ACR Convergence 2024
Sex Differences in Serum Proteomic Profiles of Males and Females with Psoriatic Arthritis
Steven Dang¹, Xianwei Li², Liqun Diao², Joan Wither³, Igor Jurisica⁴, Vinod Chandran⁵ and Lihi Eder⁶, ¹Women's College Hospital, Institute of Medical Science, University of Toronto, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) affects males and females equally, but differences exist in the clinical presentation and treatment response. The biological mechanisms driving these differences…
Abstract Number: 2312 • ACR Convergence 2024
National Prevalence of Psoriatic Arthritis in the United States: Data from National Health and Nutrition Examination Survey [NHANES]
Dilli Poudel¹, Rashmi Dhital² and Paras Karmacharya³, ¹Vanderbilt University, Nashville, TN, Brentwood, TN, ²UC San Diego, Brentwood, TN, ³Vanderbilt University, Nashville, TN, Hermitage, TN
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease which significantly impacts quality of life and healthcare costs. However, true US population-level prevalence data is…
Abstract Number: 2329 • ACR Convergence 2024
Feasibility of a Streamlined Approach for Psoriatic Arthritis Screening and Symptom Assessment
Gretchen Ball¹, Hassan Hamade², Sarah Romanelli², Melissa Zundell², Sangyoon Shin², Thami Senthilkumaran², Angela Lamb², Saakshi Khattri³, Lourdes Perez Chada⁴, Joseph Merola⁵ and Alice Gottlieb⁶, ¹Albert Einstein College of Medicine, Ridgefield, CT, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Mount Sinai Medical Center, New York, NY, ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵UT Southwestern Medical Center, Newton, MA, ⁶Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is frequently undiagnosed and/or undertreated. Given the elevated risk of disability with treatment delays, we launched a quality improvement initiative to…
Abstract Number: 2349 • ACR Convergence 2024
Predictive Potential of Serum Metabolites Associated with Treatment Response to Interleukin -17 Inhibitors in Patients with PsA
Abigail Cave¹, Sheng Han Li², Nikita Looby³, Max Kotiyar⁴, Igor Jurisica⁵, Vathany Kulasingam⁶, Proton Rahman⁷ and Vinod Chandran⁸, ¹Dalhousie University, Alliston, ON, Canada, ²Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada, ³Psoriatic Arthritis Program Schroeder Arthritis Institute, Toronto, Canada, ⁴Data Science Discovery Centre for Chronic Dsiease, Krembil Research Institute, Toronto, Canada, ⁵Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, ⁶Laboratory Medicine Program, Unviersity Health Network, Toronto, Canada, ⁷Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, ⁸University of Toronto, Toronto, ON, Canada
Background/Purpose: There is an unmet need to improve treatments for patients with Psoriatic Arthritis (PsA). Biologic disease-modifying antirheumatic drugs (bDMARDs) such as interleukin-17 inhibitors (IL-17i)…
Abstract Number: 2582 • ACR Convergence 2024
Efficacy and Safety of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Patients with Active PsA: 24-Week Results from a Global, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Iain McInnes¹, Laura Coates², Philip Mease³, Alexis Ogdie⁴, Arthur Kavanaugh⁵, Lihi Eder⁶, Georg Schett⁷, Alan Kivitz⁸, Nuala Brennan⁹, Alex Godwood⁹, Eva Cullen⁹, Kristian Reich⁹, Christopher Ritchlin¹⁰ and Joseph F. Merola¹¹, ¹University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵University of California San Diego, La Jolla, CA, ⁶University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Altoona Center for Clinical Research, Duncansville, PA, ⁹MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁰Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ¹¹UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Sonelokimab is a novel humanized Nanobody designed to inhibit IL-17A and IL-17F and penetrate clinically relevant sites of inflammation. The 24-week Phase 2 ARGO…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].